Cellbricks Therapeutics

Cellbricks Therapeutics is a preclinical biotech company based in Berlin, Germany, and Boston, USA, focused on pioneering the future of regenerative medicine and longevity. The firm develops advanced, cell-based human tissue therapeutics to restore lost tissue and organ function. Their core technology integrates a proprietary light-based biofabrication system with deep tech, AI-driven tissue engineering, and biomedicine to produce scalable, immune-compatible tissue grafts for clinical use. They aim to address conditions where current solutions, such as injectable cell therapies or organ transplantation, are limited due to issues like cell retention or organ scarcity.

Cellbricks Therapeutics was founded in 2015 by a team including Alexander Leutner (Co-CEO), Dr. Tobias Lam (CTO and creator of the bioprinting technology), and Alexander Thomas (Soft Tissue Program Lead). The company was established to tackle the critical problem of tissue dysfunction, where patients suffer from a lack of reliable solutions to restore lost cell and organ function. Their mission is to transform healthcare by providing functional, scalable, and immune-compatible biofabricated tissues that seamlessly integrate with the body.

Cellbricks Therapeutics is a recipient of investments rather than an investment firm. The company recently secured approximately €10 million in new capital, including a €7 million Seed round, in March 2026. This funding was led by Silicon Roundabout Ventures, with participation from Germany's Federal Agency for Breakthrough Innovation (SPRIND) and existing investors like ACT Venture Partners. This capital is intended to accelerate preclinical validation of their biofabricated tissue implants for soft tissue repair, wound healing, and trauma care, and to build the biological and manufacturing foundations for 3D-bioprinted viable human organs.

The Cellbricks Therapeutics team brings together extensive scientific, clinical, and business expertise, boasting over 100 years of combined experience in tissue engineering. Key leadership includes Alexander Leutner, Co-CEO (Business) and Co-founder, who previously founded and successfully exited a deep-tech startup. Dr. Simon MacKenzie, Co-CEO (Therapeutic Programs), has 25 years of experience leading biotech and pharma therapeutics teams across the US, EU, and Asia. Dr. Kathy Kordy, MD, Chief Medical Officer, has 20 years of experience as a medic and drug developer, formerly at Johnson & Johnson and Novartis. Dr. Tobias Lam, CTO and Co-founder, is the creator of Cellbricks' bioprinting technology with 10 years of experience in 3D-bioprinting. Michael Kring, CFO, was formerly the Group CFO at BioNTech SE, bringing 20 years of financial modeling and controlling expertise. Troy Dale serves as Chairman of the board, with 30 years of experience as a pharmaceutical executive.